Phase II proof-of-concept data presented at last week's American Heart Association meeting in Los Angeles provide further evidence to support the safety and efficacy of the anti-PCSK9 class of mAbs. Cross-study comparisons are difficult but results for two of the most advanced mAbs - REGN727 from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY), and AMG 145 from Amgen Inc. (NASDAQ:AMGN) - suggest the products have comparable efficacy. Pfizer Inc. (NYSE:PFE) also provided a first glimpse at POC data for its RN316.

AMG 145 and REGN727 were administered subcutaneously while RN316 was delivered intravenously. (A) Maximum mean percentage changes from baseline LDL